. Clinical course of a 62-year-old male patient with HBeAg-positive CHB who received liver transplantation because of acute-on-chronic liver failure. This patient was followed at 6 months interval without any antiviral therapy before week 0, when serum ALT, bilirubin and HBV DNA levels were 55 IU/L, 0.6 mg/dL and 3.1×10 8 IU/mL, respectively. At 12 weeks, those levels increased to 282 IU/L, 0.8 mg/dL and 2.8×10 9 IU/mL, respectively. The patient was requested to be followed without antiviral therapy even though ALT level was elevated more than 2 times the ULN. At 14 weeks, serum ALT level was 314 IU/L and bilirubin level was 0.7 mg/d. At 16 weeks, the patients visited the emergency room early because of severe anorexia and nausea. Serum ALT, bilirubin and HBV DNA levels were 2,039 IU/L, 19 mg/dL, 3.85×10 8 IU/mL, respectively. Entecavir was introduced immediately. At 18 weeks, the serum bilirubin level increased to 35.3 mg/dL and hepatic encephalopathy developed in this patient. The patient received emergent liver transplantation and recovered completely.
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